Last reviewed · How we verify

NCT06789016

Dexmedetomidine for ESPB in Pain Management After Pediatric Idiopathic Scoliosis Surgery

Completed Phase 4 Last updated 13 April 2026
What this trial tests

Phase 4 trial testing Dexmedetomidine in Scoliosis Idiopathic in 60 participants. Completed in 31 March 2026.

Timeline
1 February 2025
Primary endpoint
25 March 2026
31 March 2026

Quick facts

Lead sponsorPoznan University of Medical Sciences
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment60
Start date1 February 2025
Primary completion25 March 2026
Estimated completion31 March 2026
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Poznan University of Medical Sciences

Who can join

Adults 10 to 18, any sex, with Scoliosis Idiopathic or Scoliosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Effect of perineurial dexmedetomidine on erector spinal plane block duration for pediatric, idiopathic scoliosis surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

Other recruiting trials for Scoliosis Idiopathic

Currently open trials in the same condition.

Other Poznan University of Medical Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06789016.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing